Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc’s UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics’ GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.In 2024, Myriad Genetics earned about $45 million from GeneSight testing through UnitedHealthcare, with$40 million from commercial plans and $5 million from managed M ...